1. The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy
- Author
-
Lukas Müller, Simon Johannes Gairing, Roman Kloeckner, Friedrich Foerster, Eva Maria Schleicher, Arndt Weinmann, Jens Mittler, Fabian Stoehr, Moritz Christian Halfmann, Christoph Düber, Peter Robert Galle, and Felix Hahn
- Subjects
Carcinoma ,Hepatocellular ,Immunotherapy ,Response evaluation criteria in solid tumors ,Diagnostic imaging ,Treatment outcome ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Early tumor shrinkage (ETS) has been identified as a promising imaging biomarker for patients undergoing immunotherapy for several cancer entities. This study aimed to validate the potential of ETS as an imaging biomarker for patients undergoing immunotherapy for hepatocellular carcinoma (HCC). Methods We screened all patients with HCC that received immunotherapy as the first or subsequent line of treatment at our tertiary care center between 2016 and 2021. ETS was defined as the reduction in the sum of the sizes of target lesions, between the initial imaging and the first follow-up. The ETS was compared to the radiologic response, according to the modified response evaluation criteria in solid tumors (mRECIST). Furthermore, we evaluated the influence of ETS on overall survival (OS), progression-free survival (PFS), and the alpha-fetoprotein (AFP) response. Results The final analysis included 39 patients with available cross-sectional imaging acquired at the initiation of immunotherapy (baseline) and after 8–14 weeks. The median ETS was 5.4%. ETS was significantly correlated with the response according to mRECIST and with the AFP response. Patients with an ETS ≥10% had significantly longer survival times after the first follow-up, compared to patients with
- Published
- 2022
- Full Text
- View/download PDF